Trial Profile
A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Zelminemab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Amgen
- 24 Nov 2020 Results published in the Cephalalgia
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 09 Aug 2018 Planned End Date changed from 18 Dec 2018 to 4 Feb 2019.